Voya Investment Management LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 524,054 shares of the biopharmaceutical company's stock after selling 1,321,457 shares during the period. Voya Investment Management LLC's holdings in Gilead Sciences were worth $78,110,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the company. PFS Partners LLC boosted its stake in Gilead Sciences by 101.1% during the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 96 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $25,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $29,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $25,000. Finally, Toth Financial Advisory Corp raised its holdings in shares of Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 100 shares during the last quarter. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Price Performance
NASDAQ GILD opened at $168.98 on Thursday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The firm has a market capitalization of $209.59 billion, a PE ratio of -53.47 and a beta of 0.35. The company's 50 day simple moving average is $156.37 and its 200 day simple moving average is $142.23.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analysts' expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm's quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.47 earnings per share. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences's dividend payout ratio (DPR) is -103.80%.
Recent Gilead Sciences Headlines
Here are a few of the latest headlines about GILD:
- Positive Sentiment: Gilead signed royalty-free licensing agreements with three generic manufacturers to enable potential future access to its experimental Ebola antiviral obeldesivir in 127 countries, subject to regulatory authorization. This supports the drug’s reach, though near-term revenue is unlikely. Article: Gilead partners with generic manufacturers
- Negative Sentiment: Barclays reaffirmed its Hold rating and cited a $160 price target, indicating limited upside at the share levels referenced in recent coverage. That cautious stance may weigh on sentiment. Article: Barclays reaffirms Hold rating
- Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares, and insider Johanna Mercier sold 28,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which makes them less informative as signals about near-term company prospects, but insider sales can still add modest pressure to sentiment. Article: CFO share sale
Insider Transactions at Gilead Sciences
In other news, EVP Keeley Cain Wettan sold 3,399 shares of the business's stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president owned 5,360 shares of the company's stock, valued at approximately $879,629.60. The trade was a 38.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 102,619 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares of the company's stock, valued at approximately $96,632,794.28. This trade represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 237,709 shares of company stock valued at $39,799,137 in the last quarter. Company insiders own 0.30% of the company's stock.
Wall Street Analysts Forecast Growth
GILD has been the subject of several analyst reports. Barclays boosted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the stock an "equal weight" rating in a research report on Monday. Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a report on Friday, October 30th. Morgan Stanley raised their target price on Gilead Sciences from $163.00 to $183.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. BMO Capital Markets reaffirmed an "outperform" rating and set a $184.00 target price on shares of Gilead Sciences in a research note on Friday, October 30th. Finally, Bank of America lifted their target price on Gilead Sciences from $168.00 to $172.00 and gave the company a "buy" rating in a research note on Tuesday, October 20th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $171.63.
Get Our Latest Stock Analysis on GILD
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.